Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
Date:7/27/2009

BETHESDA, Md., July 27 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, August 6, 2009, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its financial results for the second quarter of 2009. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 pm Central European Time) on Thursday, August 6, 2009.

To participate in this conference call, dial 866-730-5770 (U.S.) or 857-350-1594 (international), passcode: 56008602. The audio webcast can be accessed at www.micromet-inc.com.

A replay of the call will be available from 12:00 pm Eastern Time on August 6, 2009 (6:00 pm Central European Time) through Thursday, August 13, 2009. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 59290657.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients wit
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
2. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
3. Micromet, Inc. Reports Third Quarter 2008 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
5. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
6. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
7. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
9. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
10. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 BioHealth Innovation, Inc. (BHI), ... innovations and increasing access to early-stage funding in ... capitalist, Tania Fernandez , Ph.D., has joined the ... be a member of the management team for a ... $50 million in seed and early-stage equity investments to ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX ... commercializing the next,generation of monoclonal antibodies based on ... Morhet, CEO and Chairman, will,present at the 7th ... Mr. Morhet,s thirty-minute presentation to potential investors ...
... NOVATO, Calif., Oct. 28 , Financial Highlights ($ in millions, except per share data), Item ... Q3 2007 Comparison Total BioMarin Revenue $72.6 ... Product Revenue $33.3 ... $38.2 ...
... DiaGenic ASA (OSL:DIAG),today announced that it has ... leading panEuropean provider of gene expression-based,diagnostic testing ... following,CE marking scheduled in early2009, DiaGenic will ... in Europe its innovative blood-based,gene-expression diagnostic test ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... available in German . ... most expensive foods in the world. Because they grow underground, ... the distinctive smell of truffles is not only of interest ... the direction of the Goethe University Frankfurt have discovered that ... bacteria which are trapped inside truffle fruiting bodies. , White ...
(Date:9/30/2014)... pregnanteven with IVF? Here,s some hope: A new research ... The FASEB Journal , explains how scientists developed ... PAWP, which induced embryo development in human and mouse ... by the sperm cell during fertilization. , "We believe ... paradigm shift in our understanding of human fertilization by ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... Sanford-Burnham Medical Research Institute, a nonprofit research institution ... the world, and Intrexon Corporation, a leading synthetic ... accelerate stem cell research. Under the agreement, Sanford-Burnham ... and gene regulation technologies that are not currently ...
... This press release is available in Spanish ... scientists are developing strategies to help livestock producers control ... in the United States. An economic ... (ARS) Agroecosystem Management Research Unit (AMRU) in Lincoln, Neb., ...
... drugs are taken off the market and a major reason ... reporting the development of a new way to predict those ... which could save patients from severe side effects and save ... of Chemical Information and Modeling . Yoshihiro Yamanishi and ...
Cached Biology News:Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 2Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 3Treating stable flies in pastures 2
Taq DNA polymerase, 10,000U...
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Biology Products: